Grunenthal GmbH - Strategic SWOT Analysis Review

Grunenthal GmbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.

This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.

Scope

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – GlobalData’s summarization of the company’s business strategy.
- SWOT analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list of key locations and subsidiaries of the company, including contact details.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.

Highlights

Grunenthal GmbH (Grunenthal) is a research-oriented pharmaceutical company. The company researches, develops, produces and markets products for the treatment of pain and innovative formulations of established active substances. It provides new chemical entities including opioids for moderate to severe pain, vanilloid receptors and KCNQ channel openers for chronic neuropathic pain; and the Bradykinin receptor for the treatment of chronic diseases with inflammation. Grunenthal focuses on discovering new methods to treat pain and developing new platform technologies for drug delivery. The company operates along with its subsidiaries in Europe, Australia, Latin America and the US. It has production plants in Germany, Italy, Switzerland and Ecuador. Grunenthal is headquartered in Aachen, Germany.

Grunenthal GmbH Key Recent Developments

Jun 07, 2016: Grunenthal Appoints Gabriel Baertschi as Chairman of the Corporate Executive Board and Chief Executive Officer Effective October 1, 2016
Mar 03, 2016: Drug Discovery Collaboration between Grunenthal and Axxam
Feb 22, 2016: Patheon Selected by Grünenthal to Develop Drugs Using INTAC Abuse Deterrent Formulations Technology
Feb 10, 2016: Grunenthal sets a strong sign of commitment for the future of their Research & Development
Jan 06, 2016: Grünenthal's Innovative Medicines Unit Opens its First Innovation Hub to Further Strengthen the Company's Networked Research and Development Approach

Reasons to Buy

- Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
- Identify potential customers and suppliers with this report’s analysis of the company’s business structure, operations, major products and services and business strategy.
- Understand and respond to your competitors’ business structure and strategies with GlobalData’s detailed SWOT analysis. In this, the company’s core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
- Examine potential investment and acquisition targets with this report’s detailed insight into the company’s strategic, business and operational performance.

Note: Some sections may be missing if data is unavailable for the company.

Frequently Asked Questions